Receptor–ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma

INTRODUCTION: Currently, programmed cell death-1 (PD-1)-targeted treatment is ineffective for a sizable minority of patients, and drug resistance still cannot be overcome. METHODS: To explore the mechanisms of immunotherapy and identify new therapeutic opportunities in lung adenocarcinoma (LUAD), da...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Shengqiang, Zeng, Lingyan, Yang, Ying, Liu, Zhiqiang, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154538/
https://www.ncbi.nlm.nih.gov/pubmed/37152010
http://dx.doi.org/10.3389/fonc.2023.1170942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154538/
https://www.ncbi.nlm.nih.gov/pubmed/37152010
http://dx.doi.org/10.3389/fonc.2023.1170942

Ejemplares similares